This IPO surprised me. PacBio has burned through so much VC funding, maybe they felt they couldn't go that route again, or their investors were impatient. Their rollout has been so slow, and they've dramatically scaled back the applications for their instrument due to technical issues, basically ceding the only market worth big $$ (large scale human sequencing). I wonder if they'll end up following Helicos.
News 
Market Data 
Discover 
AI
